Tandem Health, founded in Stockholm in 2023, has become the reference AI scribe in Europe: a reported $9.5 million seed followed by a $50 million Series A led by Kinnevik, and usage across more than a thousand healthcare organisations in the Nordics, UK, Germany, France and Spain.
Look at Tandem's own product pages, though, and the first thing they tell you is not an accuracy number or an AI claim. It is a certification: MDR Class IIa, the EU's medical-device designation, displayed above the fold on every page.
Why a certificate beats a benchmark
Class IIa certification represents something competitors cannot copy in a quarter: roughly two years of regulatory work, a quality-management system, and notified-body audits. It is also the ticket that makes institutional buyers comfortable. Tandem's distribution masterstroke — an integration with Accurx, the messaging platform used by the overwhelming majority of UK GP practices — reportedly put it in front of some 200,000 NHS professionals without selling to them one by one. That deal is hard to imagine without the certification behind it.
The lesson for everyone else
In regulated healthcare markets, trust signals outrank feature lists. The interesting question for any new entrant is not "how do we match the certificate?" — it is "what is the equivalent trust signal in our market, and how do we earn it early?" In India, that conversation points toward ABDM alignment and radical transparency about data handling rather than European device law. Different certificate; same principle.